May disordered protein cause serious drug side effect?

Drug Discovery Today

Volumn 19, Issue 4, 2014, Pages 367-372

  Tou, Weng Ieong ^a   Chen, Calvin Yu Chian ^a,b,c,d  

^a CHINA MEDICAL UNIVERSITY   (Taiwan)

^b ASIA UNIVERSITY   (Taiwan)

^c CHINA MEDICAL UNIVERSITY BEIGANG HOSPITAL   (Taiwan)

^d Massachusetts Institute of Technology Cambridge   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID A RECEPTOR; BENZODIAZEPINE; CASEIN KINASE I; CHLORDIAZEPOXIDE; CIRCADIAN RHYTHM SIGNALING PROTEIN; CRYPTOCHROME 1; CRYPTOCHROME 2; DIAZEPAM; DIPHENHYDRAMINE; DOXYLAMINE; ESTAZOLAM; ESZOPICLONE; FLURAZEPAM; HERBACEOUS AGENT; HISTAMINE RECEPTOR; HYPNOTIC AGENT; INTRINSICALLY DISORDERED PROTEIN; LIGUSTICUM CHUANXIONG EXTRACT; MELATONIN RECEPTOR; MUSCARINIC M1 RECEPTOR; POLYPEPTIDE; PROTEIN BMAL1; QUAZEPAM; SECBUTABARBITAL; SEDATIVE AGENT; TEMAZEPAM; TRANSCRIPTION FACTOR CLOCK; TRIAZOLAM; UNINDEXED DRUG; ZALEPLON; ZOLPIDEM TARTRATE; HYPNOTIC SEDATIVE AGENT;

BEHAVIOR THERAPY; CHINESE HERB; CHINESE MEDICINE; CIRCADIAN RHYTHM; COGNITIVE THERAPY; COMPUTER AIDED DESIGN; DRUG DESIGN; DRUG MECHANISM; DRUG RESEARCH; DRUG TARGETING; GLYCYRRHIZA; HERBAL MEDICINE; HUMAN; INSOMNIA; MOLECULE; PORIA; PROTEIN CONFORMATION; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; REVIEW; SEMEN ZIZIPHISPINOSAE; SLEEP DISORDER; SLEEP WAKING CYCLE; TRADITIONAL MEDICINE; CHEMISTRY; METABOLISM; SLEEP INITIATION AND MAINTENANCE DISORDERS;

CIRCADIAN RHYTHM SIGNALING PEPTIDES AND PROTEINS; DRUG DESIGN; HUMANS; HYPNOTICS AND SEDATIVES; PROTEIN CONFORMATION; SLEEP INITIATION AND MAINTENANCE DISORDERS;

EID: 84899509292     PISSN: 13596446     EISSN: 18785832     Source Type: Journal    
DOI: 10.1016/j.drudis.2013.10.020     Document Type: Short Survey

References (66)

1. K.L. Lichstein et al. Quantitative criteria for insomnia Sleep 24 2001 334
2. D.J. Buysse Insomnia JAMA 309 2013 706 716
3. T. Roth et al. Prevalence and perceived health associated with insomnia based on DSM-IV-TR; International Statistical Classification of Diseases and Related Health Problems, Tenth Revision; and Research Diagnostic Criteria/International Classification of Sleep Disorders. Second Edition criteria: results from the America Insomnia Survey Biol. Psychiatry 69 2011 592 600
4. Available at: http://www.fda.gov/.
5. M.M. Ghoneim Flurazepam (Dalmane) - a new hypnotic J. Iowa Med. Soc. 63 1973 444 446
6. H.K. Uhthoff et al. A clinical study of quazepam in hospitalized patients with insomnia J. Int. Med. Res. 9 1981 288 291
7. G.J. Blake Quazepam for insomnia Nursing 21 1991 118
8. L.F. Fabre Jr. et al. Multiclinic double-blind comparison of triazolam and flurazepam for seven nights in outpatients with insomnia J. Clin. Pharmacol. 17 1977 402 409
9. L.F. Fabre Jr., and W.T. Smith Multi-clinic cross-over comparison of triazolam (Halcion) and placebo in the treatment of co-existing insomnia and anxiety in anxious out-patients Dis. Nerv. Syst. 38 1977 487 491
10. L.F. Fabre Jr. et al. Preference studies of triazolam with standard hypnotics in out-patients with insomnia J. Int. Med. Res. 4 1976 247 254
11. R.A. Dominguez et al. Estazolam in the treatment of insomnia Psychopharmacol. Bull. 22 1986 278 280
12. T. Roehrs et al. Dose-related effects of estazolam on sleep of patients with insomnia J. Clin. Psychopharmacol. 3 3 1983 152 156
13. J.R. Cuanang, and L. Limos Treatment of insomnia with temazepam: double-blind, placebo-controlled evaluation Clin. Ther. 4 1982 402 412
14. J.M. Fillingim Double-blind evaluation of the efficacy and safety of temazepam in outpatients with insomnia Br. J. Clin. Pharmacol. 8 1979 73 77
15. C. Maggini et al. Evaluation of the effectiveness of temazepam on the insomnia of patients with neurosis and endogenous depression Arzneimittel-Forschung 19 1969 1647 1652
16. G. Chouinard Issues in the clinical use of benzodiazepines: potency, withdrawal, and rebound J. Clin. Psychiatry 65 Suppl. 5 2004 7 12
17. R. Priest et al. Efficacy of zolpidem in insomnia Eur. Psychiatry 12 Suppl. 1 1997 5 14
18. J.D. Hoehns, and P.J. Perry Zolpidem: a nonbenzodiazepine hypnotic for treatment of insomnia Clin. Pharm. 12 1993 814 828
19. B.A. Stotsky Sodium butabarbital for emotional disorders and insomnia Dis. Nerv. Syst. 33 1972 798 803
20. G. Laustsen Eszopiclone (lunesta) for treatment of insomnia Nurse Pract. 30 2005 67 68
21. S.T. Melton et al. Eszopiclone for insomnia Ann. Pharmacother. 39 2005 1659 1666
22. A.M. Wessell, and C.W. Weart Eszopiclone (Lunesta) for treatment of transient and chronic insomnia Am. Fam. Physician 71 2005 2359 2360
23. A.G. Israel, and J.A. Kramer Safety of zaleplon in the treatment of insomnia Ann. Pharmacother. 36 2002 852 859
24. M. Dooley, and G.L. Plosker Zaleplon: a review of its use in the treatment of insomnia Drugs 60 2000 413 445
25. C.Y. Chen A novel integrated framework and improved methodology of computer-aided drug design Curr. Top. Med. Chem. 13 2013 965 988
26. A.L. Hopkins, and C.R. Groom The druggable genome Nat. Rev. Drug Discov. 1 2002 727 730
27. J.R. Horn, and B.K. Shoichet Allosteric inhibition through core disruption J. Mol. Biol. 336 2004 1283 1291
28. J.A. Hardy, and J.A. Wells Searching for new allosteric sites in enzymes Curr. Opin. Struct. Biol. 14 2004 706 715
29. D.F. Ceccarelli et al. An allosteric inhibitor of the human Cdc34 ubiquitin-conjugating enzyme Cell 145 2011 1075 1087
30. T.J. Ritchie, and I.M. McLay Should medicinal chemists do molecular modelling? Drug Discov. Today 17 2012 534 537
31. P.L. Lowrey, and J.S. Takahashi Mammalian circadian biology: elucidating genome-wide levels of temporal organization Ann. Rev. Genomics Hum. Genet. 5 2004 407 441
32. Y. Fu et al. An hPer2 phosphorylation site mutation in familial Advanced Sleep-Phase Syndrome Am. J. Hum. Genet. 69 2001 597
33. Y. Xu et al. Functional consequences of a CKI delta mutation causing familial advanced sleep phase syndrome Nature 434 2005 640 644
34. K.A. Wafford, and B. Ebert Emerging anti-insomnia drugs: tackling sleeplessness and the quality of wake time Nat. Rev. Drug Discov. 7 2008 530 540
35. J.P. Wisor et al. Dopaminergic role in stimulant-induced wakefulness J. Neurosci. 21 2001 1787 1794
36. M. Naughton et al. A review of the role of serotonin receptors in psychiatric disorders Hum. Psychopharmacol. 15 2000 397 415
37. M.B. Passani et al. The histamine H3 receptor as a novel therapeutic target for cognitive and sleep disorders Trends Pharmacol. Sci. 25 2004 618 625
38. F.E. Simons H1-receptor antagonists. Comparative tolerability and safety Drug Saf. 10 1994 350 380
39. M.L. Dubocovich Melatonin receptors: role on sleep and circadian rhythm regulation Sleep Med. 8 Suppl. 3 2007 34 42
40. J. Velazquez-Moctezuma et al. Effect of specific M1, M2 muscarinic receptor agonists on REM sleep generation Brain Res. 503 1989 128 131
41. H.A. Baghdoyan et al. Localization of muscarinic receptor subtypes in brain stem areas regulating sleep Neuroreport 5 1994 1631 1634
42. J.T. Willie et al. Distinct narcolepsy syndromes in Orexin receptor-2 and Orexin null mice: molecular genetic dissection of non-REM and REM sleep regulatory processes Neuron 38 2003 715 730
43. T.S. Kilduff, and C. Peyron The hypocretin/orexin ligand-receptor system: implications for sleep and sleep disorders Trends Neurosci. 23 2000 359 365
44. A.K. Dunker et al. Intrinsically disordered protein J. Mol. Graph. Model. 19 2001 26 59
45. Y. Cheng et al. Rational drug design via intrinsically disordered protein Trends Biotechnol. 24 2006 435 442
46. K. Sanderson Databases aim to bridge the East-West divide of drug discovery Nat. Med. 17 2011 1531
47. J. Skolnick, and M. Gao Interplay of physics and evolution in the likely origin of protein biochemical function Proc. Natl. Acad. Sci. U. S. A. 110 2013 9344 9349
48. C.Y.C. Chen TCM Database@Taiwan: the world's largest traditional Chinese medicine database for drug screening in silico PLoS ONE 6 2011 e15939
49. T.Y. Tsai et al. iScreen: world's first cloud-computing web server for virtual screening and de novo drug design based on TCM database@Taiwan J. Comput. Aid. Mol. Des. 25 2011 525 531
50. W.I. Tou et al. Drug design for neuropathic pain regulation from traditional Chinese medicine Sci. Rep. 3 2013 844
51. Y.A. Tsou et al. Uroporphyrinogen decarboxylase as a potential target for specific components of traditional Chinese medicine: a virtual screening and molecular dynamics study PLoS ONE 7 2012 e50087
52. K.Y. Chen et al. In silico identification of potent pancreatic triacylglycerol lipase inhibitors from traditional Chinese medicine PLoS ONE 7 2012 e43932
53. W.I. Tou, and C.Y. Chen In silico investigation of potential SRC kinase ligands from traditional Chinese medicine PLoS ONE 7 2012 e33728
54. S.S. Chang et al. Two birds with one stone? Possible dual-targeting H1N1 inhibitors from traditional Chinese medicine PLoS Comput. Biol. 7 2011 e1002315
55. S.S. Chang et al. High performance screening, structural and molecular dynamics analysis to identify H1 inhibitors from TCM Database@Taiwan Mol. Biosyst. 7 2011 3366 3374
56. S.C. Yang et al. Identifying HER2 inhibitors from natural products database PLoS ONE 6 2011 e28793
57. S.C. Yang et al. Identification of potent EGFR inhibitors from TCM Database@Taiwan PLoS Comput. Biol. 7 2011 e1002189
58. T.T. Chang et al. In silico pharmacology suggests ginger extracts may reduce stroke risks Mol. Biosyst. 7 2011 2702 2710
59. K.C. Chen et al. Traditional Chinese medicine, a solution for reducing dual stroke risk factors at once? Mol. Biosyst. 7 2011 2711 2719
60. C.Y.C. Chen et al. What is the effective component in suanzaoren decoction for curing insomnia? Discovery by virtual screening and molecular dynamic simulation J. Biomol. Struct. Dyn. 26 2008 57 64
61. Z.L. You et al. Effects on the expression of GABA(A) receptor subunits by jujuboside A treatment in rat hippocampal neurons J. Ethnopharmacol. 128 2010 419 423
62. X.J. Wang et al. Potential drug targets on insomnia and intervention effects of Jujuboside A through metabolic pathway analysis as revealed by UPLC/ESI-SYNAPT-HDMS coupled with pattern recognition approach J. Proteomics 75 2012 1411 1427
63. B. Yang et al. Metabolomic study of insomnia and intervention effects of Suanzaoren decoction using ultra-performance liquid-chromatography/electrospray- ionization synapt high-definition mass spectrometry J. Pharm. Biomed. Anal. 58 2012 113 124
64. C.Y. Chen, and W.I. Tou How to design a drug for the disordered proteins? Drug Discov. Today 18 2013 910 915
65. S.K. Sadiq et al. Kinetic characterization of the critical step in HIV-1 protease maturation Proc. Natl. Acad. Sci. U. S. A. 109 2012 20449 20454
66. W.A. Lim et al. Design principles of regulatory networks: searching for the molecular algorithms of the cell Mol. Cell 49 2013 202 212